Quick Takeaways: Why It Matters? Data for LPT‑CBD strengthens the scientific case for long‑acting, injectable CBD as a legitimate chronic pain option, not just a wellness supplement, which can increase veterinarian openness to cannabinoid-based therapies. The sustaine...
Quick Takeaways: Why It Matters? The recall may temporarily weaken confidence in Neogen’s veterinary portfolio and open space for rival hyaluronate or wound-care products. It also underscores regulatory and safety scrutiny around off-label use, likely prompting v...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...
Quick Takeaways: Why It Matters? A-DHA-PT gives veterinary neurologists a standardized, high‑dose DHA option developed under academic supervision, potentially making nutritional add‑on therapy a more routine consideration in dogs with idiopathic epilepsy where pharmacologic con...
